Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen, a pharmaceutical company has sold its North American development and marketing rights for Apokyn to Britannia Pharmaceuticals.
Subscribe to our email newsletter
Apokyn (apomorphine hydrochloride injection) is used to treat acute hypomobility ‘off’ episodes linked to advanced Parkinson’s disease.
Following the move, Ipsen will not record Apokyn sales in its accounts from 30 November 2011
Britannia on the other hand will take charge of continuity of supply and support of Apokyn through USWorldMeds, which will commercialise Apokyn in the US.